CJC-1295 + Ipamorelin in India

Name: CJC-1295 No DAC + Ipamorelin Blend
Brand: Prime Peptide
SKU: PR-CDP10
Price: 4199.0 INR
Availability: InStock

PRODUCT OVERVIEW

What is CJC-1295 No DAC + Ipamorelin?

CJC-1295 No DAC + Ipamorelin is a laboratory research blend containing two distinct peptide components. CJC-1295 No DAC, also known as Modified GRF 1-29, is associated with growth hormone-releasing hormone receptor signaling, while Ipamorelin is associated with growth hormone secretagogue receptor 1a signaling.

The blend can support controlled study designs involving parallel receptor pathways, pituitary-response timing, growth-hormone signaling, and peptide co-formulation analysis. Evidence for the individual components does not by itself establish combination-specific synergy or outcomes.

Purity≥99%

Molecular WeightMixture; no single molecular weight

SequenceCJC-1295 No DAC: Y-dA-DAIFTNSYRKVLGQLSARKLLQDIMSR-NH2 Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2

StorageStore refrigerated at 2–8°C

FormLyophilized peptide blend

Research UseFor in-vitro laboratory research only

Dual GHRH-Receptor and GHSR1a Signaling Model

The CJC-1295 No DAC component is modeled through growth hormone-releasing hormone receptor signaling. The Ipamorelin component is modeled through growth hormone secretagogue receptor 1a signaling. These are distinct upstream pathways that can be examined within the same experimental design.

Co-formulation alone does not establish biological synergy. Any conclusion about combination-specific interaction or outcome requires direct experimental evidence under the relevant study conditions.

RESEARCH AREAS

CJC-1295 No DAC + Ipamorelin Potential Use Cases

Product-specific research applications associated with Prime Peptide CJC-1295 No DAC + Ipamorelin.

Dual GHRH-receptor and GHSR1a signaling research

Pituitary response models

Growth-hormone signaling timing studies

Comparative peptide pathway research

Co-formulation analytical studies

Component interaction study designs

KEY BENEFITS

CJC-1295 No DAC + Ipamorelin Research Highlights

Key research-oriented characteristics connected to Prime Peptide CJC-1295 No DAC + Ipamorelin.

Two defined peptide components in one research blend
Supports parallel receptor-pathway study designs
Component identities remain independently traceable
Suitable for controlled comparative laboratory workflows

SPECIFICATIONS

CJC-1295 No DAC + Ipamorelin Molecular Data

Molecular specifications for Prime Peptide CJC-1295 No DAC + Ipamorelin
Molecular Formula	Mixture; no single molecular formula
Molecular Weight	Mixture; no single molecular weight
Purity	≥99%
Appearance	White lyophilized powder
Solubility	Water-soluble
Storage	Store refrigerated at 2–8°C
Research Use	For in-vitro laboratory research only

3D Structure · Representative Model

BIOLOGICAL & MOLECULAR TARGETS

CJC-1295 No DAC + Ipamorelin Research Targets

Growth hormone-releasing hormone receptor

GHRHR

G protein-coupled receptor

A G protein-coupled receptor on pituitary somatotroph cells that mediates growth hormone-releasing hormone signaling and supports endogenous growth hormone secretion.

View reference ↗

Growth hormone secretagogue receptor 1a

GHSR-1a

G protein-coupled receptor

GHSR-1a is a G protein-coupled receptor activated by ghrelin and synthetic growth-hormone secretagogues. Ipamorelin research examines receptor-mediated signaling associated with pituitary growth-hormone release.

View reference ↗

SCIENTIFIC SOURCES

CJC-1295 No DAC + Ipamorelin Citations & References

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Journal of Clinical Endocrinology & Metabolism 2006

Randomized controlled studies of long-acting, DAC-containing CJC-1295 in healthy adults reported sustained increases in GH and IGF-1. This citation supports the CJC-1295 pathway context but is not direct formulation-specific evidence for CJC-1295 No DAC.

Read publication →

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

Journal of Clinical Endocrinology & Metabolism 2006

In healthy men, long-acting DAC-containing CJC-1295 increased mean and trough GH and IGF-1 while preserving GH pulsatility. The formulation distinction must be retained when discussing No DAC material.

Read publication →

Advances in the detection of growth hormone releasing hormone synthetic analogs

Drug Testing and Analysis 2021

Analytical research treated CJC-1295 and CJC-1295 with Drug Affinity Complex as distinguishable GHRH synthetic analog materials, supporting explicit formulation-level terminology.

Read publication →

Ipamorelin, the first selective growth hormone secretagogue

European Journal of Endocrinology 1998

Primary pharmacology study describing Ipamorelin as the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2 and comparing its growth-hormone-releasing profile with other secretagogues in pituitary-cell and animal models. PMID: 9849822.

Read publication →

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Pharmaceutical Research 1999

Human dose-escalation study modeling Ipamorelin pharmacokinetics and the time course of growth-hormone response after intravenous infusion. The paper reports dose-proportional disposition and an episodic growth-hormone response model. PMID: 10496658.

Read publication →

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption

Xenobiotica 1998

Comparative animal pharmacokinetic study evaluating Ipamorelin and related peptidyl growth-hormone secretagogues across administration routes, including clearance, excretion, metabolic recovery and nasal absorption. PMID: 9879640.

Read publication →

TERMINOLOGY

CJC-1295 No DAC + Ipamorelin Glossary

CJC-1295 No DAC + Ipamorelin blend — A laboratory research blend containing CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin as two distinct peptide components.

The CJC-1295 No DAC + Ipamorelin blend is a co-formulated research material containing two distinct peptides. CJC-1295 No DAC is associated with growth hormone-releasing hormone receptor signaling, while Ipamorelin is associated with growth hormone secretagogue receptor 1a signaling.

Because the blend is a mixture rather than a single molecule, it does not have one molecular formula, molecular weight, sequence, or CAS number. Evidence for each component does not by itself establish combination-specific synergy or outcomes.

Also known as: CJC-1295 No DAC + Ipamorelin, Modified GRF 1-29 + Ipamorelin, CJC No DAC Ipamorelin blend, CJC-1295 without DAC and Ipamorelin

CJC-1295 No DAC — A non-DAC GHRH-analogue designation commonly used for modified GRF(1-29); it should be distinguished from albumin-binding CJC-1295 with DAC.

CJC-1295 No DAC is a marketplace and research-material designation commonly associated with a modified 29-amino-acid growth hormone-releasing hormone fragment. It lacks the Drug Affinity Complex used by long-acting albumin-binding CJC-1295. Consequently, evidence from clinical studies of CJC-1295 with DAC should not be treated as direct formulation-specific evidence for the No DAC material.

Also known as: Modified GRF(1-29), Mod GRF 1-29, CJC-1295 without DAC Source ↗

Modified GRF(1-29) — A modified analogue of the biologically active 1-29 fragment of human growth hormone-releasing factor.

Modified GRF(1-29) refers to an analogue based on the active N-terminal 29-residue portion of human growth hormone-releasing factor. Research on GHRH(1-29) analogues established that this shortened region can retain growth-hormone-releasing activity, while sequence modifications can alter stability and potency.

Also known as: Mod GRF 1-29, modified growth hormone-releasing factor 1-29 Source ↗

Drug Affinity Complex (DAC) — A conjugation strategy used in long-acting CJC-1295 to bind endogenous albumin and extend exposure.

The Drug Affinity Complex in CJC-1295 enables covalent association with circulating albumin, producing prolonged pharmacokinetic exposure. The absence of this component is the defining distinction implied by the term CJC-1295 No DAC.

Also known as: DAC, albumin-binding conjugation Source ↗

Growth hormone pulsatility — The episodic pattern in which growth hormone is secreted in distinct pulses rather than at a constant rate.

Growth hormone pulsatility describes the naturally episodic release of growth hormone. A study of long-acting CJC-1295 with DAC reported increased mean and trough GH while preserving the pulsatile secretion pattern; that result pertains to the DAC formulation.

Source ↗

Ipamorelin — A synthetic pentapeptide growth-hormone secretagogue studied for selective pituitary growth-hormone release.

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Published pharmacology describes it as a growth-hormone secretagogue investigated in receptor, pituitary-cell, animal and human PK/PD studies.

Also known as: NNC 26-0161 Source ↗

Growth hormone secretagogue — A compound studied for stimulating growth-hormone release through secretagogue-receptor signaling.

A growth hormone secretagogue is a peptide or non-peptide compound investigated for stimulating pituitary growth-hormone release through growth hormone secretagogue receptor signaling. This pathway is distinct from direct activation of the GHRH receptor.

Also known as: GHS, GH secretagogue Source ↗

Growth hormone secretagogue receptor 1a — The functional ghrelin receptor subtype involved in growth-hormone secretagogue signaling.

Growth hormone secretagogue receptor 1a, abbreviated GHSR-1a, is the signaling-competent ghrelin receptor subtype. It is a G protein-coupled receptor used in binding and functional assays for ghrelin and synthetic secretagogues.

Also known as: GHSR-1a, Ghrelin receptor, Growth hormone secretagogue receptor Source ↗

COMMON RESEARCH QUESTIONS

CJC-1295 No DAC + Ipamorelin FAQ

What is the CJC-1295 No DAC + Ipamorelin blend?

It is a laboratory research blend containing two distinct peptide components: CJC-1295 No DAC, also called Modified GRF 1-29, and Ipamorelin. The blend is modeled as a mixture and not as a new single molecular entity.

Which receptor pathways are represented in the blend?

CJC-1295 No DAC is associated with the growth hormone-releasing hormone receptor pathway. Ipamorelin is associated with growth hormone secretagogue receptor 1a, also called GHSR1a. These are distinct upstream signaling pathways that can be examined within the same controlled laboratory design.

Does the blend have a single molecular formula or molecular weight?

No. It is a mixture of two independently defined peptides rather than one covalently linked molecule. Each component retains its own molecular formula, molecular weight, amino-acid sequence, and CAS identity, so the blend should not be assigned one combined molecular identity.

Does combining CJC-1295 No DAC and Ipamorelin establish biological synergy?

No conclusion of synergy should be made from co-formulation alone. The cited studies describe the individual components and their respective pathways. Any claim about combination-specific interaction, magnitude, or outcome would require direct experimental evidence using the blend under the relevant study conditions.